Verge Genomics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 61

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 37

Verge Genomics General Information

Description

Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegenerative diseases. The company's platform utilizes machine learning to develop therapeutics, specifically for neurological diseases, and can analyze datasets of any size to identify targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 131 Oyster Point Bouleverd
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 131 Oyster Point Bouleverd
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650)

Verge Genomics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verge Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 20-Mar-2024 Completed Generating Revenue
7. Later Stage VC (Series C) 08-Sep-2023 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B1) 15-Dec-2021 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A1) 07-Oct-2020 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 16-Jul-2018 Completed Clinical Trials - Phase 1
3. Seed Round 28-Oct-2015 Completed Pre-Clinical Trials
2. Accelerator/Incubator 18-Aug-2015 $120K $120K Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Verge Genomics’s complete valuation and funding history, request access »

Verge Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B1
Series A6
Series A5
Series A4
Series A3
Series A2 1,698,104 $0.000100 6% $2.65 $2.65 1x $2.65 3.26%
Series A1 13,622,216 $0.000100 6% $3.31 $3.31 1x $3.31 26.12%
To view Verge Genomics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Verge Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegener
Drug Discovery
South San Francisco, CA
61 As of 2025

Denver, CO
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verge Genomics Competitors (59)

One of Verge Genomics’s 59 competitors is Cerecin, a Venture Capital-Backed company based in Denver, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cerecin Venture Capital-Backed Denver, CO
AltPep Venture Capital-Backed Seattle, WA
Mitobridge Formerly VC-backed Cambridge, MA
Alzheon Venture Capital-Backed Framingham, MA
PAQ Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 59 competitors. Get the full list »

Verge Genomics Patents

Verge Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4118087-A1 Substituted furo[3,2-d]pyrimidines and uses thereof Pending 09-Mar-2020
US-20230146395-A1 Substituted pyrimidines and uses thereof Pending 09-Mar-2020
AU-2021207804-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020
CA-3167339-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020
EP-4090426-A1 Substituted pyrazolo-pyrimidines and uses thereof Pending 13-Jan-2020 C07D487/04
To view Verge Genomics’s complete patent history, request access »

Verge Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verge Genomics Investors (37)

Investor Name Investor Type Holding Investor Since Participating Rounds
BOLD Longevity Growth Growth/Expansion Minority
Ferrer Internacional Corporation Minority
Koru Capital (New York) Venture Capital Minority
Alexion Corporation Minority
AstraZeneca Corporation Minority
You’re viewing 5 of 37 investors. Get the full list »

Verge Genomics FAQs

  • When was Verge Genomics founded?

    Verge Genomics was founded in 2015.

  • Where is Verge Genomics headquartered?

    Verge Genomics is headquartered in South San Francisco, CA.

  • What is the size of Verge Genomics?

    Verge Genomics has 61 total employees.

  • What industry is Verge Genomics in?

    Verge Genomics’s primary industry is Drug Discovery.

  • Is Verge Genomics a private or public company?

    Verge Genomics is a Private company.

  • What is Verge Genomics’s current revenue?

    The current revenue for Verge Genomics is .

  • How much funding has Verge Genomics raised over time?

    Verge Genomics has raised $176M.

  • Who are Verge Genomics’s investors?

    BOLD Longevity Growth, Ferrer Internacional, Koru Capital (New York), Alexion, and AstraZeneca are 5 of 37 investors who have invested in Verge Genomics.

  • Who are Verge Genomics’s competitors?

    Cerecin, AltPep, Mitobridge, Alzheon, and PAQ Therapeutics are some of the 59 competitors of Verge Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »